RO7204239
Sponsors
F. Hoffmann-La Roche AG, Hoffmann-La Roche
Conditions
Facioscapulohumeral Muscular Dystrophy (FSHD)Facioscapulohumeral muscular dystrophy (FSHD)ObesityOverweightOverweight With One Weight Related ComorbiditySpinal Muscular Atrophy (SMA)Type 2 Diabetes Mellitus
Phase 1
Phase 2
A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Risdiplam (RO7034067) in Participants With Spinal Muscular Atrophy
Active, not recruitingNCT05115110
Start: 2022-06-02End: 2026-10-28Updated: 2026-09-09
A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy
Active, not recruitingNCT05548556
Start: 2023-02-07End: 2026-10-23Updated: 2026-09-15
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Pharmacodynamics, Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy
Active, not recruitingCTIS2022-503117-36-00
Start: 2022-12-01Target: 27Updated: 2025-02-10
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
Active, not recruitingNCT06965413
Start: 2025-05-05End: 2027-03-31Updated: 2026-09-09
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial to Assess Efficacy, Safety, and Tolerability of RO7204239 in Combination with Tirzepatide in Participants with Obesity or Overweight with at least One Weight-Related Comorbidity
Active, not recruitingCTIS2024-519561-22-00
Start: 2025-07-07Target: 78Updated: 2025-09-26